Outcome Domains for Studies of Acute and Chronic Gout

REFERENCES

1. 1.↵
   1. Martinon F,
   2. Pétrilli V,
   3. Mayor A,
   4. et al.

   Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;44:237–41.

   OpenUrl
2. 2.↵
   1. Vitart V,
   2. Rudan I,
   3. Hayward C,
   4. Gray NK,
   5. Floyd J,
   6. Palmer CN,
   7. et al.

   AF.SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008;40:437–42.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Chang SJ,
   2. Chen CJ,
   3. Tsai FC,
   4. Lai HM,
   5. Tsai PC,
   6. Tsai MH,
   7. Ko YC

   . Associations between gout tophus and polymorphisms 869T/C and −509C/T in transforming growth factor beta1 gene. Rheumatology 2008;47:617–21.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Becker MA,
   2. Schumacher HR, Jr,
   3. Wortmann RL,
   4. MacDonald PA,
   5. Eustace D,
   6. Palo WA,
   7. et al.

   Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450–61.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Sherman MR,
   2. Saifer MG,
   3. Perez-Ruiz F

   . PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60:59–68.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Schumacher HR, Jr,
   2. Edwards LN,
   3. Perez-Ruiz F,
   4. Becker M,
   5. Chen LX,
   6. Furst DE,
   7. et al.

   OMERACT 7 Special Interest Group. Outcome measures for acute and chronic gout. J Rheumatol 2005;32:2452–5.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Schumacher HR,
   2. Taylor W,
   3. Joseph-Ridge N,
   4. Perez-Ruiz F,
   5. Chen LX,
   6. Schlesinger N,
   7. et al.

   Outcome evaluations in gout. J Rheumatol 2007;34:1381–5.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Taylor WJ,
   2. Schumacher HR, Jr,
   3. Baraf HS,
   4. Chapman P,
   5. Stamp L,
   6. Doherty M,
   7. et al.

   A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis 2008;67:888–91.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. World Health Organization

   . International Classification of Functioning, Disability and Health. Geneva:WHO; 2001.
10. 10.↵
    1. Cieza A,
    2. Ewert T,
    3. Ustun TB,
    4. Chatterjee S,
    5. Kostanjsek N,
    6. Stucki G

    . Development of ICF Core Sets for patients with chronic conditions. J Rehabil Med 2004;Suppl 44:9–11
11. 11.↵
    1. Grill E,
    2. Zochling J,
    3. Stucki G,
    4. Mittrach R,
    5. Scheuringer M,
    6. Liman W,
    7. et al.

    International Classification of Functioning, Disability and Health (ICF). Core set for patients with acute arthritis. Clin Exp Rheumatol 2007;25:252–8.

    OpenUrlPubMed
12. 12.↵
    1. Grainger R,
    2. Taylor W,
    3. Dalbeth N,
    4. Perez-Ruiz F,
    5. Singh JA,
    6. Waltrip RW,
    7. et al.

    Progress in measurement instruments for acute and chronic gout studies. J Rheumatol 2009;36:2346–55.

    OpenUrlAbstract/FREE Full Text